非那雄胺(Finasteride) - 药物靶点：5α-reductase_在研适应症：雄激素脱发，脱发，前列腺增生症_专利_临床

概要

基本信息

简介Finasteride，商业名称为PROSCAR®，是一种5α-还原酶抑制剂药物，主要用于治疗男性前列腺增生症（BPH），改善症状、降低急性尿潴留的风险以及降低需要手术（包括经尿道前列腺电切术和摘除前列腺）的风险。这种药物于1992年在美国获得首次批准，由默克公司生产。PROSCAR (finasteride)是一种合成的4-氮杂甾体化合物，是一种特异性的类固醇II型5α-还原酶抑制剂，可抑制细胞内的酶将雄激素睾酮转化为5α-二氢睾酮（DHT）。

药物类型

小分子化药

别名

(5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide、Finasteride (JAN/USP/INN)、非那雄胺（奎安）

+ [47]

靶点

5α-reductase

作用方式

抑制剂

作用机制

5α-reductase抑制剂(类固醇5α还原酶抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

+ [3]

非在研机构

Merck Sharp & Dohme Corp.Merck Frosst Canada Ltd.

Polichem SA (Switzerland)

+ [3]

权益机构

Daewoong Pharmaceutical Co., Ltd.

Almirall SA

Inventage Lab, Inc.

+ [2]

最高研发阶段批准上市

首次获批日期

美国 (1992-06-19),

前列腺增生症

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C23H36N2O2

InChIKeyDBEPLOCGEIEOCV-WSBQPABSSA-N

CAS号98319-26-7

关联

143

项与非那雄胺相关的临床试验

NCT06944145

/ Not yet recruiting临床2期IIT

New Treatment Strategies and Epigenetic Biomarker for Management of BPH

SRD5A2 is a critical enzyme for prostatic development and growth, and the SRD5A2 inhibitor, finasteride, is used to treat benign prostatic hyperplasia (BPH). SRD5A2 is absent in 30% of normal adult men, which explains the resistance of a subset of patients to this commonly prescribed drug. This project proposes new combination therapies (5-ARI+raloxifene) and evaluates novel non-invasive biomarkers, based on alternative pathways that lead to prostatic enlargement.

开始日期2025-06-01

申办/合作机构

Beth Israel Deaconess Medical Center, Inc.

NCT06826001

/ Not yet recruiting临床2期IIT

COMPARISON OF EFFICACY OF TOPICAL FINESTERIDE VERSUS TOPICAL MINOXIDAL IN TREATMENT OF ANDROGENETIC ALOPECIA

Androgenetic alopecia (AGA)is the most common form of alopecia. It predominantly affects males, but there has been a significant surge in female preponderance too, over the last decade Minoxidil belong to the anti-hypertensive class but it also affects the potassium channels present in vascular smooth muscles and hair follicles. This potassium channel activity may stimulate the microcirculation around the hair follicles and induces arteriolar vasodilation, thereby encouraging conditions conducive to hair growth Topical administration of finasteride offers the potential to reduce systemic effects related to its mechanism of action by preferentially inhibiting 5-a reductase in the scalp, as has been suggested in recent years so in this study we are going to compare efficacy of topical minoxidil versus topical finasteride in treatment of androgenetic alopecia

开始日期2025-02-01

申办/合作机构

Sheikh Zayed Medical College

TCTR20240926001

/ Active, not recruiting临床3期IIT

Efficacy and safety of different doses of topical finasteride in the treatment of male androgenetic alopecia

开始日期2024-12-16

申办/合作机构-

100 项与非那雄胺相关的临床结果

登录后查看更多信息

100 项与非那雄胺相关的转化医学

登录后查看更多信息

100 项与非那雄胺相关的专利（医药）

登录后查看更多信息

4,268

项与非那雄胺相关的文献（医药）

2025-09-01·NEUROPHARMACOLOGY

Early postnatal inhibition of neurosteroid synthesis changes the later-life adverse outcome of neonatal asphyxia in rats

Article

作者: Löscher, Wolfgang ; Welzel, Björn ; Schmidt, Ricardo

Birth asphyxia (BA) is a common cause of hypoxic-ischemic encephalopathy (HIE), neonatal seizures, and detrimental neurodevelopment. Brain levels of neurosteroids such as allopregnanolone rise in response to acute hypoxic stress, which is thought to represent an endogenous protective mechanism that reduces excitotoxicity in the developing brain. In the present study, we investigated how inhibition of neurosteroid synthesis by the steroid 5α-reductase inhibitor finasteride affects the adverse outcomes of BA/HIE. Intermittent asphyxia was induced in neonatal rats at postnatal day 11. Finasteride (50 mg/kg) was administered immediately before asphyxia. Behavioral and cognitive tests were performed over the subsequent 14 months, which corresponds to ∼50 % of the lifespan of the outbred rat strain used. In contrast to our expectation, finasteride decreased the severity and duration of the neonatal seizures and did not increase mortality. Subsequent behavioral experiments showed no adverse development of motor function, but finasteride-treated rats exhibited increased anxiety-like behavior in the open field, elevated plus-maze, and light-dark box tests. The increased anxiety-like behavior was correlated with enhanced mossy fiber sprouting in the hippocampal CA3a region. While vehicle-treated post-asphyxial rats showed a serious decline in cognitive functions, this was not observed in the finasteride-treated group. One possible explanation of the latter finding is that a significant loss of CA3c neurons in the dorsal hippocampus was only determined in vehicle-treated but not finasteride-treated post-asphyxial rats. Overall, the present study indicates that the role of neurosteroids in BA and its adverse outcome is much more complex than previously thought.

2025-07-01·EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Enhanced ex vivo skin retention of bicalutamide using a nano-in-micro composite: Drug-loaded lipid vesicles in a dissolving microarray patch

Article

作者: Borrego-Sánchez, Ana ; Correia, Mafalda ; Guillot, Antonio José ; Paiva-Santos, Ana Cláudia ; Martínez-Navarrete, Miquel ; Bernabeu-Martínez, J Alejandro

Antiandrogens are a family of drugs that block the biological effects of androgens, which are commonly used to treat a plethora of androgen-dependent conditions. However, their effectiveness highly depends on treatment compliance and their use is not exempt from side effects. Bicalutamide (BIC) is a testosterone blocker that, due to its peripheral tissue selectivity, offers the advantage of fewer side effects compared to other antiandrogens such as finasteride or dutasteride. In this study, BIC-loaded lipid vesicles (LVs) were developed and incorporated into a PVP/PVA-based Dissolving Microarray Patches (BIC-LVs@DMAPs) for BIC skin local delivery. First, the mechanical and insertion properties of the BIC-LVs@DMAPs were assessed. Then, the in vitro biocompatibility of the formulation was determined in keratinocytes. Finally, the effectiveness of the formulation to deliver BIC through skin was explored ex vivo using murine skin. BIC-LVs@DMAPs exhibited optimal mechanical and insertion properties to effectively perforate the stratum corneum and facilitate the passage of BIC-LVs. Ex vivo studies demonstrated the efficacy of BIC-LVs@DMAPs to improve the skin retention of BIC, while in vitro cytotoxicity results ensured their safety profile. Overall, these results pave the way for further in vivo studies and clinical application to improve the current early stages androgenetic alopecia topical treatments.

2025-06-01·JOURNAL OF APPLIED TOXICOLOGY

The Effects of Finasteride on Apoptosis, Antioxidants, and Cytokines in Experimental Diabetes Rats.

Article

作者: Aksit, Hasan ; Celebi, Murat ; Altun, Eren ; Celebi, Cagla ; Aksit, Dilek

Diabetes mellitus (DM) is one of the five leading causes of death worldwide. Finasteride is an inhibitor of type 2 5-alpha reductase enzyme. In this study, we aimed to investigate the effects of finasteride on apoptosis, oxidative stress, antioxidants, and cytokines in the liver, kidney, and testis in an experimental diabetes model in rats. Thirty-two male rats were randomly divided into four equal groups as follows: control, finasteride (30 mg/kg 14 days by gastric gavage), diabetes, and diabetes+finasteride. Malondialdehyde (MDA), superoxide dismutase (SOD), and total antioxidant status (TAS) levels in liver, kidney, and testis tissues, and nitric oxide (NO), interleukin 6 (IL-6), and tumor necrosis factor-α (TNF-α) levels in blood samples were examined. In addition, tissue sections were evaluated immunohistochemically (B-cell lymphoma 2 (Bcl-2), Bcl-2 associated X protein (Bax)) and histopathologically. Induction of diabetes with streptozotocin resulted in an increase MDA, NO, IL-6, TNF-α levels whereas TAS and SOD decreased compared to the control group. Diabetes+Finasteride group was compared with the diabetes group decrease in MDA, NO, IL-6, TNF-α levels, and increase in TAS and SOD levels were observed. Finasteride suppressed apoptosis through the down regulation of Bax and the induction of the expression of Bcl-2 in the liver and kidney. Finasteride administration ameliorated some histopathological changes and decreased oxidative stress, apoptosis, and inflammation while increasing the antioxidant defense system in the STZ-induced diabetes group. In conclusion, finasteride might show a protective effect by suppressing oxidative stress and apoptosis and downregulation of proinflammatory cytokines in diabetic rats with its antioxidant and antiapoptotic effects. Human trials are needed before clinical application.

246

项与非那雄胺相关的新闻（医药）

2025-06-06

·EINPresswire

Understanding the Effects of Dihydrotestosterone (DHT) on the Prostate and Treatment Options for Elevated Levels

New Research Highlights DHT’s Role in Prostate Health and Emerging Therapies to Manage Hormone Imbalance Understanding the role of dihydrotestosterone (DHT) is essential for those undergoing testosterone replacement therapy.” — Chris Rue, FNP-C NEW ORLEANS, LA, UNITED STATES, June 6, 2025 / EINPresswire.com / -- Dihydrotestosterone (DHT), a potent androgen derived from testosterone, plays a critical role in the development and maintenance of male characteristics. However, medical experts and researchers are sounding the alarm about its potential impact on prostate health, especially when levels become elevated. DHT is primarily synthesized in the prostate, liver, skin, and hair follicles through the enzymatic conversion of testosterone by 5-alpha reductase. While essential for male development, excessive DHT levels have been strongly linked to benign prostatic hyperplasia (BPH) and an increased risk of prostate enlargement, which can lead to urinary problems and decreased quality of life in aging men. Effects of Elevated DHT on the Prostate: • Prostate Enlargement: Elevated DHT stimulates excessive growth of prostate tissue, contributing to BPH. • Urinary Symptoms: Increased prostate volume can compress the urethra, causing frequent urination, difficulty starting urination, and weak urinary flow. • Potential Cancer Risk: Though the relationship is complex, some studies suggest high DHT levels may influence prostate cancer progression. According to recent clinical reviews, men over the age of 50 are especially vulnerable, with over 50% developing some form of prostate enlargement by age 60. Treatment Options to Lower Elevated DHT Levels: Medical professionals emphasize early intervention and hormone regulation as key strategies. The most common treatments include: 1. 5-Alpha Reductase Inhibitors: Medications such as finasteride (Proscar) and dutasteride (Avodart) block the conversion of testosterone to DHT, reducing prostate size and alleviating symptoms. 2. Natural DHT Blockers: Compounds like saw palmetto extract, pumpkin seed oil, and green tea catechins are under investigation for their mild DHT-lowering effects. 3. Lifestyle Changes: A diet rich in anti-inflammatory foods, regular exercise, and weight management may help regulate hormone levels. 4. Hormonal Monitoring: Regular blood tests to track testosterone and DHT levels can aid in early detection and intervention. Dr. Michael Reynolds, a board-certified urologist, commented, “DHT is essential, but when imbalanced, it can become a catalyst for prostate issues. We now have evidence-based strategies to bring levels back to a healthier range.” About the Prostate Health Initiative The Prostate Health Initiative is a nationwide educational campaign aimed at raising awareness about male hormone balance and its effects on long-term urological health. Through collaboration with healthcare providers and research institutions, the initiative seeks to empower men to make informed choices about their prostate health. ________________________________________ Chris Rue Metairie Optimal Performance Enhancement +1 504-265-5491 info@mopeclinic.com Visit us on social media: LinkedIn Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2025-05-28

·生物世界

“头等大事”的新认知与新希望

撰文丨吴文育排版丨王多鱼一、雄激素性秃发（AGA）：不容忽视的“头等大事” 雄激素性秃发（AGA）是全球最常见的脱发类型，我国男性患病率高达 21.3%，女性约6.0%【1】。其病理特征为毛囊微型化及毛发周期紊乱，与遗传、雄激素（例如二氢睾酮）敏感性升高密切相关。临床表现为：男性 AGA：前额发际线后移（M型）、头顶稀疏（O型），严重者发展为 Hamilton-Norwood 分级 Ⅵ 级以上；女性 AGA：头顶毛发弥漫性稀疏（Ludwig分级），发缝增宽，但前额发际线通常保留【2】。左图为 Hamilton-Norwood 分级，右图为 Ludwig 分级图除了临床表现外，拉发试验（pull test）对于诊断也有一定的辅助作用。在不洗头（一般持续 3-5 天不洗头）的情况下，用拇指、食指和中指，从头发根部轻轻捏住约 50-60 根头发，顺着头发方向轻拉，如脱落头发超过 6 根，则拉发试验阳性，提示有活动性脱发【5】。鉴别诊断需与斑秃（突发的片状脱发）、休止期脱发（均匀性脱发）及瘢痕性秃发（无毛囊开口）区分，结合毛发镜（毛干粗细不均、毳毛比例增加）及激素检测（血清睾酮、二氢睾酮水平，排除内分泌疾病）可明确诊断【3】。二、生活管理为基础，医学干预为核心若发现自己出现雄激素性秃发迹象时，无需过度焦虑。保持良好生活习惯极为关键，比如作息规律，杜绝熬夜；饮食均衡，少吃高糖、高脂、辛辣食物；学会自我减压，避免长期精神紧绷。但仅靠生活方式调整通常难以满足需求，还需积极寻求专业医学治疗。三、权威指南：雄激素性秃发的规范治疗《中国雄激素性秃发诊疗指南（2023）》明确指出：由于雄激素性秃发（AGA）呈慢性渐进性过程，因此早期诊断和早期治疗十分重要，治疗越早，疗效也越好。药物治疗 AGA 的主要治疗方法，包括内服和外用药物。内服药物包括男性患者可服用 1mg 非那雄胺片，女性患者可使用螺内酯或孕激素类药物等。外用药物米诺地尔则是 AGA 药物治疗的一线选择，男女均可使用【4】。临床上常用的第一代米诺地尔是溶液剂（MTS），包括了常见的酊剂和搽剂；2024 年中国上市了第二代米诺地尔泡沫剂（MTF），为脱发患者带来新希望。相比第一代米诺地尔溶液剂，第二代米诺地尔泡沫剂有 2.85 倍皮下毛囊蓄积量，快速起效；同时不含丙二醇，降低了头皮过敏反应的发生率，可提升使用者长期维持治疗的依从性。除此之外，如果药物治疗坚持超过半年未见明显改善，可以在医生的指导下联合物理治疗或者植发手术等方式，以达到治疗目标。希望广大患者在发现自己可能患有雄激素性秃发问题后，能够及早就诊并坚持规范治疗，在医生的指导下合理使用药物，早日摆脱脱发困扰。参考文献：[1] 中华医学会皮肤性病学分会. 中国雄激素性秃发诊疗指南（2023）[J]. 中华皮肤科杂志, 2024, 57(1): 1-10.[2] Olsen EA, et al. A multicenter trial of 5% minoxidil foam in AGA[J]. J Am Acad Dermatol, 2007, 57(5): 767-774. DOI:10.1016/j.jaad.2007.06.007.[3] Blume-Peytavi U, et al. 5% MTF vs. 2% MTS in women[J]. J Am Acad Dermatol, 2011, 65(6): 1126-1134.[4] 中国整形美容协会. 雄激素性脱发诊断与治疗指南（2023）[EB/OL]. (2024-01-01)[2024-03-15]. http://www.csda.org.cn.[5] 张学军。皮肤性病学 [M]. 9 版。北京：人民卫生出版社，2018: 144-146.设置星标，不错过精彩推文开放转载欢迎转发到朋友圈和微信群微信加群为促进前沿研究的传播和交流，我们组建了多个专业交流群，长按下方二维码，即可添加小编微信进群，由于申请人数较多，添加微信时请备注：学校/专业/姓名，如果是PI/教授，还请注明。点在看，传递你的品味

临床研究疫苗

2025-05-21

·PRNewswire

Eden Launches Access to Hair Wellness Program Connecting Adults to Prescription Hair Care Through Independent Licensed Providers and Pharmacies

The new program provides access to virtual consultations and pharmacy-filled prescriptions for oral minoxidil and finasteride under clinician supervision. DENVER, May 21, 2025 /PRNewswire/ -- Eden, the leading health platform connecting individuals with licensed providers and pharmacies focused on metabolic health, today announced the launch of its clinician-guided Hair Wellness Program. The program enables adults across the U.S. to explore prescription-based options such as oral minoxidil and finasteride following a virtual consultation with a licensed provider. If a prescription is issued, it is filled by a state-licensed compounding pharmacy and shipped directly to the member's door. Other oral therapies (such as minoxidil and finasteride or spironolactone) are expected to become available later this year through Eden's provider and pharmacy network. Eden's program is designed to offer individuals convenient access to medical evaluations and pharmacy-prepared treatments under the supervision of licensed professionals. The process requires telehealth visits and includes follow-up support to help patients stay informed and aligned with their provider's care plan. "Hair-related concerns are often part of broader conversations around aging and wellness," said Adam McBride, CEO of Eden. "We created this program to give adults the ability to speak with a provider from home and access treatments that are typically hard to get outside of specialist clinics." Key Program Components: Telehealth Intake – Patients complete a secure health questionnaire and meet virtually with a licensed provider to assess eligibility for treatment. Prescription Fulfillment – If appropriate, providers may prescribe oral minoxidil or finasteride. These are compounded medications prepared by state licensed pharmacies and shipped directly to the patient. Ongoing Support – Eden's care coordination team offers follow-up check-ins at key milestones to help patients stay on track and informed throughout their care journey. Oral minoxidil is a vasodilator that has been studied for off-label use in addressing certain hair-related concerns. Oral finasteride is FDA-approved for male pattern hair loss and may also be prescribed off-label in other contexts, based on a provider's clinical judgment. Compounded medications are customized for individual patients by licensed pharmacies and are not FDA-approved. They are prepared in accordance with provider orders to meet unique medical needs. "This is about giving patients access to licensed care, clear guidance, and personalized formulations," said Dr. Rebecca Emch, PharmD, VP of Pharmacy and Medical Operations at Eden. "Our platform makes it easier for people to receive provider input and trusted treatment options." "People want solutions that are professional, personalized, and backed by expertise, not more guesswork from store shelves or unregulated practitioners," said Josh Khan, President and Co-Founder at Eden. "We're excited to expand access to care that fits into real life and supports how people want to look and feel." Pricing and Availability The Hair Wellness Program is available in all 50 states. Plans start at $29/month. Medication is included only if prescribed and clinically appropriate. About Eden Eden is a health company that connects individuals with licensed doctors, compounding pharmacies, and nutrition solutions designed to support metabolic health. Through a seamless online experience, Eden helps patients explore personalized treatment options, offering a convenient approach to overall wellness support. Certain therapies described may be prescribed off-label, based on clinical discretion. These statements have not been evaluated by the Food and Drug Administration. Compounded medications accessed via Eden's network are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. SOURCE Eden WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与非那雄胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00321	非那雄胺	G04CB01 D11AX10	DB01216

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
雄激素脱发	日本	Organon & Co.	2005-10-11
脱发	美国	Organon & Co.	1997-12-19
前列腺增生症	美国	Organon & Co.	1992-06-19

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
男性雄激素源性脱发	临床3期	比利时	Polichem SA (Switzerland)	2016-08-02
男性雄激素源性脱发	临床3期	德国	Polichem SA (Switzerland)	2016-08-02
男性雄激素源性脱发	临床3期	匈牙利	Polichem SA (Switzerland)	2016-08-02
男性雄激素源性脱发	临床3期	俄罗斯	Polichem SA (Switzerland)	2016-08-02
男性雄激素源性脱发	临床3期	西班牙	Polichem SA (Switzerland)	2016-08-02
血尿	临床2期	加拿大	Merck Frosst Canada Ltd.	2008-03-01
血精症	临床2期	加拿大	Merck Frosst Canada Ltd.	2008-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02248701 (Pubmed \| Front Neurol)	临床2期	脊髓损伤 testosterone \| estradiol \| dihydrotestosterone	12	High-dose Testosterone + Finasteride	鹽顧遞鹹淵鹹憲憲鑰鑰(鹹構艱糧遞製餘網壓鬱) = reduced more than vehicle+placebo at 12 months 憲夢築糧蓋鬱壓鏇淵襯 (鏇簾鏇繭衊願獵製觸醖 ) 更多	积极	2024-12-11
NCT02213107 (phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI), CTgov)	临床2期	复发性前列腺癌 \| 前列腺癌 \| 局限性前列腺癌 ... 更多	43	finasteride+Enzalutamide+Dutasteride	網憲鏇鏇艱襯鹹糧遞鹽 = 築糧築鏇醖獵蓋鏇夢積鹽範艱醖網簾齋餘網蓋 (選遞醖蓋積網夢鬱鑰齋, 鹽選鹹顧網獵窪蓋廠鹽 ~ 積鬱選鏇鑰壓鑰餘選醖) 更多	-	2024-11-13
NCT02213107 (ASCO2024) 人工标引	临床2期	去势敏感前列腺癌	43	Enzalutamide 16Dutasteride+ DFinasteride0.5mg daily	鹹衊糧積鹽顧獵獵獵製(鑰鏇鬱製簾獵觸製衊壓) = 構選鹹製選餘鬱窪衊鹽網願艱鹹膚鑰鹹糧壓襯 (繭構壓築艱鹹襯蓋膚鬱 ) 更多	积极	2024-05-24
THU372 (ENDO2023)	N/A	高血糖	-	Finasteride	遞遞蓋鏇獵壓製積夢願(蓋鏇築衊繭壓夢顧鑰鏇) = 夢構廠繭獵選簾遞鬱簾鹹餘鑰淵窪夢艱夢遞窪 (衊艱鑰襯淵簾願網壓淵 )	不佳	2023-10-05
NCT02248701 (CTgov)	临床2期	性腺机能减退 \| 男性生殖器官疾病 \| 脊髓损伤	33	Finasteride+Testosterone Enanthate (Testosterone Enanthate, Finasteride)	淵壓繭壓繭憲餘襯遞廠(構繭願襯糧衊餘餘築蓋) = 築襯鬱積選構獵顧構膚壓廠鹽醖遞築鏇繭鑰網 (構選網糧糧齋築餘範襯, 4.7) 更多	-	2023-09-29
NCT02248701 (CTgov)	临床2期	性腺机能减退 \| 男性生殖器官疾病 \| 脊髓损伤	33	Placebo pill (Placebo Treatment)	淵壓繭壓繭憲餘襯遞廠(構繭願襯糧衊餘餘築蓋) = 鹽選顧憲膚鑰醖鹽蓋鹽壓廠鹽醖遞築鏇繭鑰網 (構選網糧糧齋築餘範襯, 2.4) 更多	-	2023-09-29
WCD2023	N/A	雄激素脱发	28	Oral Minoxidil (2.5MG)	鏇衊築壓憲鏇膚構膚醖(衊憲衊糧夢醖鬱願窪觸) = 醖鹹築餘顧艱廠構鹽願範積築鑰艱窪鑰築餘鏇 (膚衊範簾構糧餘壓網簾 )	-	2023-07-03
WCD2023	N/A	雄激素脱发	28	Oral Finasteride (1MG)	鏇衊築壓憲鏇膚構膚醖(衊憲衊糧夢醖鬱願窪觸) = 憲夢鑰淵繭廠艱壓齋簾範積築鑰艱窪鑰築餘鏇 (膚衊範簾構糧餘壓網簾 )	-	2023-07-03
EURETINA2022	N/A	中心性浆液性脉络膜视网膜病变	-	Finasteride	獵鬱糧觸選遞壓遞壓膚(醖憲願遞蓋鏇願積夢淵) = 衊築餘醖簾壓鹹淵衊簾蓋獵廠齋衊鹹願餘簾鏇 (壓簾壓淵蓋鑰觸構鹽廠 )	-	2022-09-01
MP38-07 (AUA2022)	N/A	性功能障碍 DHT \| testosterone \| calculated free T	91	Men with persistent sexual dysfunction after discontinuation of Finasteride	獵選築觸淵衊願淵獵觸(餘餘醖壓獵壓鏇艱壓鬱) = 鹽選顧糧積鑰製憲蓋網艱繭獵築構觸獵齋鏇膚 (繭夢襯鏇繭選鑰齋網鹹 ) 更多	-	2022-05-01
ARVO2022	N/A	干眼综合征	116	Finasteride 1 mg or 2.5 mg	艱淵餘網淵齋觸壓憲衊(築鬱願遞壓繭願憲廠鹽) = 醖製遞鹽願鏇廠夢鏇鑰鬱獵製觸鹽醖築積憲襯 (膚範製繭範積鹽齋夢鹹 ) 更多	-	2022-05-01
ARVO2022	N/A	干眼综合征	116	Finasteride 5 mg	艱淵餘網淵齋觸壓憲衊(築鬱願遞壓繭願憲廠鹽) = 願淵範醖顧構獵蓋願衊鬱獵製觸鹽醖築積憲襯 (膚範製繭範積鹽齋夢鹹 ) 更多	-	2022-05-01
NCT01342367 (Prospective Trial Of Oral-Only Hormonal Therapy With Radiation, CTgov)	N/A	非转移性前列腺癌	74	bicalutamide+leuprolide+goserelin (SOC Cohort)	壓製願觸醖鹽遞壓製獵(積網積淵壓製簾築餘糧) = 鹽襯製鏇衊夢蓋醖築壓鹹壓築壓齋鏇襯壓鑰範 (積積淵夢窪範衊壓積餘, 0.04) 更多	-	2021-10-28
	N/A	非转移性前列腺癌	74	finasteride+dutasteride+bicalutamide (Oral ADT Group)	壓製願觸醖鹽遞壓製獵(積網積淵壓製簾築餘糧) = 艱蓋鏇簾壓衊蓋夢鏇淵鹹壓築壓齋鏇襯壓鑰範 (積積淵夢窪範衊壓積餘, 0.04) 更多	-	2021-10-28